News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Real-time Estimate Cboe BZX Other stock markets 02:43:16 2024-04-26 pm EDT			5-day change	1st Jan Change
884.7 ^USD	-0.67%		-1.32%	+0.76%

06:25pm	Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says	MT
02:45pm	Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says	12:25pm	MT
Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125	08:45am	MT
DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing	04:12am	AQ
Regeneron Pharmaceuticals Receives a Shareholder Proposal from John Chevedden	Apr. 25	CI
Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences	Apr. 25	DJ
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases	Apr. 25	GL
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation Crispr-Based Gene Editing for Multiple Diseases	Apr. 25	CI
Sanofi Q1 profit slips on generic competition, forex effects	Apr. 25	RE
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO	Apr. 24	GL
TD Cowen Adjusts Regeneron Pharmaceuticals' Price Target to $1,030 From $1,020, Keeps Buy Rating	Apr. 24	MT
Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	Apr. 23	MT
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)	Apr. 22	GL
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	Apr. 22	AQ
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors	Apr. 17	BU
UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating	Apr. 17	MT
The market is pinning its hopes on earnings reports	Apr. 17
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...	Apr. 17
Regeneron to defend against DOJ complaint on drug-price manipulation	Apr. 15	RE
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation	Apr. 15	RE
Regeneron Pharmaceuticals : Statement on Department of Justice Filing Related to EYLEA® (aflibercept) Injection 2 mg	Apr. 15	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Summary

Filters